PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Sildenafil

Drugs in development · updated 30 October 2026

Sildenafil: clinical trials and development status

Other names and codes: Viagra, Liqrev, Vybrique, Revatio, Mysildecard

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 13 September 1998

As of 30 October 2026 Sildenafil is in 22 active clinical trials (recruiting or ongoing, phases I–III) for 23 diseases. The most advanced phase is III.

22Active trials
IIIMost advanced phase
23Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Sildenafil and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Erectile dysfunctionIII5NCT07177326
Arterial pulmonary hypertensionII–III1NCT07824674
FatigueII–III1NCT06800092
Mental fatigueII–III1NCT06800092
NeoplasmII–III1NCT06800092
Peripheral Arterial DiseaseIII1NCT03686306
Rectal neoplasmIII1NCT06123156
Brain hypoxia-ischemiaII2NCT06098833
Urinary incontinenceII2NCT04565925
Asphyxia neonatorumII1NCT06098833
Chronic obstructive pulmonary diseaseII1NCT05061368
Congenital diaphragmatic herniaII1NCT05201144
Diffuse sclerodermaII1NCT04797286
Digital ulcerII1NCT06954597
DyspneaII1NCT05061368
HypoxiaI–II1NCT04898114
Persistent fetal circulation syndromeI–II1NCT04898114
Pulmonary hypertensionII1NCT05201144
Spinal cord injuryII1NCT04565925
Systemic sclerodermaII1NCT06954597
Traumatic brain injuryII1NCT05782244
Brain NeoplasmsEarly I1NCT07039760
Vascular diseaseEarly I1NCT06510322

Everything on Sildenafil

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch